Fig. 2From: Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective studyCumulative deaths of 404 patients during the whole follow-up. The majority of deaths developed during the first 3Â years after MSCI. year 1: the first year after MSCI; year 2: the second year after MSCI, and so forth. The numbers in each district represented the total deaths occurred in the different yearsBack to article page